title: Incidence and predictors of venous thromboembolism in post-acute care patients. A prospective cohort study.
abstract: Few studies have addressed the topic of venous thromboembolism (VTE) in patients hospitalised in rehabilitation facilities. This patient population is rapidly growing, and data aimed to better define VTE risk in this setting are needed. Primary aim of this prospective observational study was to evaluate the frequency of symptomatic, objectively confirmed VTE in a cohort of unselected consecutive patients admitted to rehabilitation facilities, after medical diseases or surgery. Further objectives were to assess overall mortality, to identify risk factors for VTE and mortality, and to assess the attitude of physicians towards thromboprophylaxis. A total of 3,039 patients were included in the study, and the median duration of hospitalisation was 26 days. Seventy-two patients (2.4%) had symptomatic VTE. The median time to VTE from admission to the long-term care unit was 13 days. According to multivariable analysis, previous VTE (hazard ratio 5.67, 95% confidence interval 3.30-9.77) and cancer (hazard ratio 2.26, 95% confidence interval 1.36-3.75) were significantly associated to the occurrence of VTE. Overall in-hospital mortality was 15.1%. Age over 75 years, male gender, disability, cancer, and the absence of thromboprophylaxis were significantly associated to an increased risk of death (multivariable analysis). In-hospital antithrombotic prophylaxis was administered to 75.1% of patients, and low-molecular-weight heparin was the most widely used agent. According to our study, patients admitted to rehabilitation facilities remain at substantially increased risk for VTE. Because this applies to the majority of these patients, there is a great need for clinical trials assessing optimal prophylactic strategies.
authors.affiliation: Internal Medicine, Cà Foncello Hospital, Treviso, Italy. gscannapieco@ulss.tv.it
authors.forename: Gianluigi
authors.initials: G
authors.lastname: Scannapieco
authors.forename: Walter
authors.initials: W
authors.lastname: Ageno
authors.forename: Andrea
authors.initials: A
authors.lastname: Airoldi
authors.forename: Erminio
authors.initials: E
authors.lastname: Bonizzoni
authors.forename: Mauro
authors.initials: M
authors.lastname: Campanini
authors.forename: Gualberto
authors.initials: G
authors.lastname: Gussoni
authors.forename: Mauro
authors.initials: M
authors.lastname: Silingardi
authors.forename: Antonella
authors.initials: A
authors.lastname: Valerio
authors.forename: Chiara
authors.initials: C
authors.lastname: Zilli
authors.forename: Ido
authors.initials: I
authors.lastname: Iori
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000378:metabolism; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage; D017052:Hospital Mortality; D006765:Hospitals, Convalescent; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology*; D011379:Prognosis; D011446:Prospective Studies; D012008:Recurrence; D012307:Risk Factors; D012737:Sex Factors; D015912:Thrombolytic Therapy; D054556:Venous Thromboembolism / Q000175:diagnosis* / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control
chemical_list: D015415:Biomarkers; D006495:Heparin, Low-Molecular-Weight